Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment

Monfrini, M., Donzelli, E., RODRIGUEZ MENENDEZ, V., Ballarini, E., Carozzi, V., Chiorazzi, A., et al. (2017). Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. EXPERIMENTAL NEUROLOGY, 288, 75-84 [10.1016/j.expneurol.2016.11.006].

Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy

MONFRINI, MARIANNA
Primo
;
DONZELLI, ELISABETTA
Secondo
;
RODRIGUEZ MENENDEZ, VIRGINIA;BALLARINI, ELISA;CAROZZI, VALENTINA ALDA;CHIORAZZI, ALESSIA;MEREGALLI, CRISTINA;CANTA, ANNALISA ROSANNA;OGGIONI, NORBERTO;AVEZZA, FEDERICA;TREDICI, GIOVANNI;CAVALETTI, GUIDO ANGELO
Penultimo
;
SCUTERI, ARIANNA
Ultimo
2017

Abstract

Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment
Articolo in rivista - Articolo scientifico
Diabetic neuropathy; Pancreatic islet transplantation; Mesenchymal stem cell; Diabetes
English
2017
288
75
84
partially_open
Monfrini, M., Donzelli, E., RODRIGUEZ MENENDEZ, V., Ballarini, E., Carozzi, V., Chiorazzi, A., et al. (2017). Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. EXPERIMENTAL NEUROLOGY, 288, 75-84 [10.1016/j.expneurol.2016.11.006].
File in questo prodotto:
File Dimensione Formato  
2017 Exp Neurol 75-84.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 3.29 MB
Formato Adobe PDF
3.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Monfrini Exp Neurol VERSIONE FINALE ACCETTATA.pdf

accesso aperto

Tipologia di allegato: Author’s Accepted Manuscript, AAM (Post-print)
Dimensione 1.36 MB
Formato Adobe PDF
1.36 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/135690
Citazioni
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 20
Social impact